key: cord-0683138-19rehmuf
authors: Caillard, Sophie; Thaunat, Olivier
title: COVID-19 vaccination in kidney transplant recipients
date: 2021-09-27
journal: Nat Rev Nephrol
DOI: 10.1038/s41581-021-00491-7
sha: f4d7d876d2f1080711d22170af538e2fc3bc32b0
doc_id: 683138
cord_uid: 19rehmuf

Kidney transplant recipients receive therapeutic immunosuppression that impairs their immune responses to the COVID-19 mRNA vaccine. For this reason, this vulnerable patient population is insufficiently protected by the standard two-dose COVID-19 vaccination programme and requires a specific follow-up to guide personalization of an intensified vaccination approach.

Patients with kidney disease are at high risk of deve loping severe COVID19. This risk is especially high in kidney transplant recipients, in whom the risk of death owing to SARS CoV2 infection is estimated to be as high as 25% (ref. 1 ). Consequently, the health authorities of numerous countries have prioritized this vulnerable population for vaccination with mRNA vaccines.

The BNT162b2 (Pfizer/BioNTech) and mRNA1273 (Moderna) vaccines comprise lipid nanoparticles con taining nucleoside modified mRNA molecules that encode the SARS CoV2 spike protein. The use of antigen encoding RNA for vaccination is a fast, highly scalable, innovative technology that is also pharmaceu tically safe because the RNA is transiently expressed and the risk of integration into the genome of the treated host is low 2 . Moreover, in addition to inducing potent CD4 + helper T cell and antibody responses, which are also induced by protein based immunizations, mRNA vaccines in general (and BNT162b2 and mRNA1273 in particular) induce strong CD8 + cytotoxic T cell responses that can eliminate infected cells, which function as 'virus factories' 2,3 .

Whether protection against COVID19 after mRNA vaccination depends mainly on cellular (cytotoxic cells) or humoral (antibodies) adaptive immune effectorstermed mechanistic correlates of protection -is not yet entirely clear and might vary depending on factors such as the virus variant or patient characteristics. However, recent reports have clearly demonstrated the importance of developing neutralizing antibodies 4 , in particular in vaccinated kidney transplant recipients 5 . Neutralizing antibodies act by binding to the spike protein of SARS CoV2, thereby eliminating extracel lular viruses and preventing their entry into host cells. Importantly, high titres of anti spike IgGs (>264 bind ing antibody units per ml), which can be measured by commercial serological tests and are much easier to perform at large scale than neutralization assays, corre late well with the presence of neutralizing antibodies and vaccine efficacy against primary symptomatic COVID19.

Although in the general population both BNT162b2 and mRNA1273 vaccines induce robust titres of anti spike IgGs that confer >94% protection against severe COVID19, many independent studies (Supplementary Table 1 ) have reported that only 4-48% of kidney transplant recipients have detectable anti spike IgGs after receiving two vaccine doses. Consequently, severe cases of COVID19 still occur in vaccinated transplant recipients 6 , which demonstrates that they are insufficiently protected by the current 'standard' COVID19 vaccination approach. Kidney transplant recipients who have not been previously infected with SARS CoV2 are more likely to generate anti spike IgGs if vaccination is performed late after transplan tation (probably owing to lower levels of immunosup pression), if they have a high glomerular filtration rate and if circulating anti spike IgGs are detectable after the first dose of vaccine. Conversely, older age, diabetes and high levels of maintenance immunosuppression are all associated with a lower vaccination response rate. Some evidence indicates that patients treated with belatacept (a T cell co stimulation blocker) or rituximab (used for B cell depletion) display low (<10%) seroconversion rates (Supplementary Table 1) .

A suboptimal response to COVID19 mRNA vac cines in transplant recipients was not entirely unex pected because these patients are known to mount poor responses to many protein subunit vaccines. Maintenance immunosuppression regimens used to prevent graft rejection commonly include a calcineurin inhibitor, which interferes with T cell activation, and an antimetabolite, such as mycophenolate mofetil (MMF), which blocks the pro liferation of activated T and B cells. Although these drugs, particularly when used in com bination and/or at high doses, impede antibody genera tion after vaccination, several reports suggest that MMF, which blocks the proliferation of follicular helper CD4 + T (T FH cells), is especially detrimental. In our preprint study, T FH cells were instrumental for the differentia tion of spike specific B cells into antibody producing plasma cells 5 .

Kidney transplant recipients receive therapeutic immunosuppression that impairs their immune responses to the COVID-19 mRNA vaccine. For this reason, this vulnerable patient population is insufficiently protected by the standard two-dose COVID-19 vaccination programme and requires a specific follow-up to guide personalization of an intensified vaccination approach. Approaches to improve COVID19 vaccine effi cacy in transplant recipients include modulation of immunosuppression -for example, temporary reduc tion or suspension of MMF treatment, or belatacept replacement -and should be evaluated on an indivi dual basis owing to the potential risk of graft rejection. Importantly, the immune mechanisms that enable the generation of protective anti spike IgGs after vaccina tion also underlie the generation of anti donor HLA antibodies, which are widely recognized as the main cause of late kidney allograft rejection. Notably, infection with SARS CoV2 usually triggers the generation of high titres of protective neutralizing anti spike IgGs in kidney transplant recipients 5 , and the main predictor of success ful seroconversion after vaccination in these patients is a previous history of COVID19; in these patients, a single dose of mRNA vaccine leads to a 100% seroconversion rate and antibody levels that are comparable to those observed in healthy volunteers 7 . These observations suggest that increasing vaccine immunogenicity might be a safer approach to improve vaccine efficacy than reducing immunosuppression.

Strategies to optimize protein subunit vaccine immuno genicity in kidney transplant recipients include the use of adjuvants, intradermal injection and high anti gen doses, but these approaches have not yet been tested for COVID19 mRNA vaccines. Given that the postinfluenza vaccine seroconversion rate in kidney transplant recipients improved when additional 'booster' doses were received, administration of a third dose of COVID19 mRNA vaccine to these patients has been authorized in France (April 2021) and in the USA (August 2021). Although a third vaccine dose was globally very well tolerated by kidney transplant recip ients who had an insufficient anti spike IgG response after two vaccine doses, the serological response was heterogeneous (Supplementary Table 1 ). Overall, this intensified vaccination approach led to a protective titre of anti spike IgG in ~40% of kidney transplant recipients. In a preprint study, predictive variables asso ciated with a successful response to the third vaccine dose included the presence of anti spike IgGs and/or spike specific IFNγ producing CD4 + T cells after the second dose 8 . By contrast, <10% of kidney transplant recipients with negative serology and a negative IFNγ releasing assay responded to the third dose 8 . These patients might instead benefit from passive transfer of anti SARS CoV2 monoclonal antibodies.

Given their increased vulnerability to severe COVID19, kidney transplant recipients need to be effectively vac cinated. Although kidney transplantation candidates receiving chronic haemodialysis also have a defective response to the COVID19 mRNA vaccine 9 , this defect is milder than that observed in transplant recipients being treated with immunosuppressive drugs. COVID19 vac cination should therefore be administered during the pre transplant waiting period. Transplant recipients with a previous history of COVID19 usually respond well to a single dose of mRNA vaccine but, for those without prior infection, assessment of anti spike IgG titres after the second dose of mRNA vaccine might be important to discriminate patients who are adequately protected from those likely to lack neutralizing anti bodies 10 . In SARS CoV2 naive kidney transplant recipients, determining anti spike IgG levels after two doses of vac cine (and, when possible, an estimation of the number of spike specific CD4 + T cells using a simple commercially available IFNγ release assay) might be useful to guide the administration of a third or fourth booster dose, or the use of primary prophylaxis with monoclonal antibodies ( fig. 1 ). Finally, although accumulating data gene rated all over the world during the first part of 2021 have enabled the development of a vaccination approach against COVID19, data regarding the duration of protection increasing vaccine immunogenicity might be a safer approach to improve vaccine efficacy than reducing immunosuppression

An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants

mRNA vaccines -a new era in vaccinology

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Comparison of infected and vaccinated transplant recipients highlights the role of Tfh and neutralizing IgG in COVID-19 protection

Occurrence of severe COVID-19 in vaccinated transplant patients

Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19

Predictive factors of response to 3rd dose of COVID-19 mRNA vaccine in kidney transplant recipients

The ROMANOV study found impaired humoral and cellular immune responses to SARS-Cov-2 mRNA vaccine in virus unexposed patients receiving maintenance hemodialysis

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

(that is, the stability of neutralizing antibody titres over time) are lacking, and the crucial question of whether kidney transplant recipients will need boosters (and when) remains to be investigated.

The authors declare no competing interests.

Supplementary information is available for this paper at https://doi.org/ 10.1038/s41581-021-00491-7.